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A study-level meta-analysis has shown that proton magnetic resonance spectroscopy is a promising prognostic
marker in neonatal hypoxic-ischemic encephalopathy. An individual patient data meta-analysis could yield a
prognostic tool with improved accuracy enabling well-founded clinical decisions. Our request to share patient
data remained unanswered by five out of 18 research groups. Another four declined collaboration for various
reasons, including own reanalysis of the data, and lack of parental consent. With less than 40% of the individual
patient data available, we refrained from pursuing the proposed study. As future patients may benefit from it,
policies mandating data sharing should be introduced.
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End-of-life decisions and withdrawal of intensive care fre-
quently precede death in newborns suffering from hypoxic-
ischemic encephalopathy [1]. These decisions, taken in the
neonatal intensive care unit, are to a large extent supported
by neuroimaging and neurophysiological findings. Accord-
ing to a recent systematic review however, these prognostic
tools, although promising, definitely lack precision [2]. In
their meta-analysis, Thayyil and coworkers found that deep
gray matter magnetic resonance biomarkers (especially
measuring lactate/acetyl aspartate ratio) have good ac-
curacy for predicting adverse outcome in neonatal enceph-
alopathy [3]. Professor Wilkinson appropriately criticized
this meta-analysis and suggested to perform an individual
patient data meta-analysis [4], a challenge we accepted.
The study protocol was published last year in Systematic
Reviews [5].
As described in the study protocol, authors of all se-
lected prognostic accuracy studies were contacted by
email. They were offered the opportunity to comment
on the study proposal. We acknowledged the challenge
of the study but emphasized the known benefits of an
individual patient data meta-analysis. We underlined the
support we got from Prof. N. Robertson, an expert in* Correspondence: pieter.degraeuwe@mumc.nl
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article, unless otherwise stated.the field. The ethical considerations were supported by
our Medical Ethics Committee and we do have the opin-
ion that the publication policy treated every contributory
group fairly.
Five out of 18 approached research groups showed a
favorable response and were ready to share raw patient
data. To our surprise, five contacted groups did not an-
swer our request for collaboration, even after two email
reminders, in which we mentioned the positive reactions
received until then. In four cases, our request was met
with a refusal. In two cases, the main reason for nonco-
operation was lack of personnel or time to retrieve the
data. We realized from the start that the effort asked for
was substantial but worth making. In the future, mandatory
release of all raw data of every published prognostic accur-
acy study could facilitate the process of individual patient
data (IPD) meta-analysis. This is in line with the growing
awareness that sharing data is an ethical obligation [6,7].
One author, contacted by phone, was reanalyzing his own
data in collaboration with another research group (although
they emailed: ‘we do not currently have personnel available
to look through all of our records’) and could therefore not
share the raw data. This argument reminded us of a paper
of Ioannidis wherein the author states that databases can
be used as ‘private goldmines not to be shared’ or as ‘public
commodity’ [8]. One author raised the issue of the lack ofed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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though legislation might differ between countries, our med-
ical ethics committee did not make an objection to the
proposed IPD meta-analysis, under the express condition
that the patient data are de-identified. It is hard to think
that parents having consented for the original study would
object to an IPD meta-analysis. We even imagine that par-
ents would disagree with the waste of their children's data
for secondary research.
All in all, even if we would be able to obtain all data
from the nonresponders, 55% of the individual patient
data at the very most will be available for the proposed
IPD meta-analysis. So, we refrain from the proposed IPD
meta-analysis and advocate instead a large prospective
multicenter study to investigate the predictive value of
MRS biomarkers simultaneously with other clinical, neu-
roimaging, and neurophysiological variables. This seems
currently the best way to investigate whether a reliable
prediction tool can be established for babies with neo-
natal encephalopathy.
Finally, while it is tempting to blame individual re-
searchers for lacking a cooperative attitude, we have to
acknowledge that there are currently no incentives for
sharing data, and the debate of sharing clinical trial data
is still ongoing. It is our hope that the general attitude
about raw data availability will change and that funders
and journals will make sharing practices mandatory for
diagnostic and prognostic studies as well [9].
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